Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Tzu Tai

Showing results (1-10 of 211) with videos related to

Pageof 22
Sort By:
Oncotarget|September 20, 2012
Bruton's tyrosine kinase: oncotarget in myelomaYu-Tzu Tai, Kenneth C Anderson
Oncotarget|January 20, 2018
Targeting CD38 alleviates tumor-induced immunosuppressionYu-Tzu Tai, Kenneth C Anderson
Expert Opinion on Biological Therapy|July 7, 2019
B cell maturation antigen (BCMA)-based immunotherapy for multiple myelomaYu-Tzu Tai, Kenneth C Anderson
Immunotherapy|September 16, 2015
Targeting B-cell maturation antigen in multiple myelomaYu-Tzu Tai, Kenneth C Anderson
Blood|July 23, 2016
A new era of immune therapy in multiple myelomaYu-Tzu Tai, Kenneth C Anderson
Bone Marrow Research|November 3, 2011
Antibody-based therapies in multiple myelomaYu-Tzu Tai, Kenneth C Anderson
Current Opinion in Pharmacology|March 17, 2004
Stem cells as a potential treatment of neurological disordersYu-Tzu Tai, Clive N Svendsen
Immunotargets and Therapy|October 29, 2020
Immunotherapeutic and Targeted Approaches in Multiple MyelomaOmar Nadeem, Yu-Tzu Tai, Kenneth C Anderson
The Journal of Trauma|May 26, 2011
Aneurysm bone cyst presented as a zygomatic mass after facial traumaYu-Tzu Tai, Pai-Chun Yen, Erh-Kang Chou
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2022
Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor ResponseShih-Feng Cho, Kenneth C Anderson, Yu-Tzu Tai
Pageof 22

Showing results (1-10 of 211) with videos related to

Sort By:
Pageof 22
Oncotarget|September 20, 2012
Bruton's tyrosine kinase: oncotarget in myelomaYu-Tzu Tai, Kenneth C Anderson
Oncotarget|January 20, 2018
Targeting CD38 alleviates tumor-induced immunosuppressionYu-Tzu Tai, Kenneth C Anderson
Expert Opinion on Biological Therapy|July 7, 2019
B cell maturation antigen (BCMA)-based immunotherapy for multiple myelomaYu-Tzu Tai, Kenneth C Anderson
Immunotherapy|September 16, 2015
Targeting B-cell maturation antigen in multiple myelomaYu-Tzu Tai, Kenneth C Anderson
Blood|July 23, 2016
A new era of immune therapy in multiple myelomaYu-Tzu Tai, Kenneth C Anderson
Bone Marrow Research|November 3, 2011
Antibody-based therapies in multiple myelomaYu-Tzu Tai, Kenneth C Anderson
Current Opinion in Pharmacology|March 17, 2004
Stem cells as a potential treatment of neurological disordersYu-Tzu Tai, Clive N Svendsen
Immunotargets and Therapy|October 29, 2020
Immunotherapeutic and Targeted Approaches in Multiple MyelomaOmar Nadeem, Yu-Tzu Tai, Kenneth C Anderson
The Journal of Trauma|May 26, 2011
Aneurysm bone cyst presented as a zygomatic mass after facial traumaYu-Tzu Tai, Pai-Chun Yen, Erh-Kang Chou
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2022
Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor ResponseShih-Feng Cho, Kenneth C Anderson, Yu-Tzu Tai
Pageof 22